GlycoMimetics puts off $64M IPO pitch

After downsizing its sought-after haul, GlycoMimetics is postponing its $64 million IPO plans, a sign that the year's investor frenzy over biotech debuts may not be welcoming all comers. Early last month, the Gaithersburg, MD-based company filed to rake in up to $86 million in a first-time offering, scaling it back to $64 million on Oct. 28. Article

Suggested Articles

An inhaled drug developed by Aridis eradicated the novel coronavirus from infected hamsters at a much lower dose than other antibody treatments.

The financing positions SparingVision to fund clinical trials of an AAV gene therapy that could stop vision deterioration in 2 million patients.

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.